23andMe CEO says consumer genetics will be as normal as at-home pregnancy tests
23andMe CEO and cofounder Anne Wojcicki says consumers don’t need experts to interpret results from genetic risk tests, and compared the information her company offers to at-home pregnancy tests. She says research by 23andMe and others has shown that the average consumer can understand the results from genetic health profiles—and how those results may, or may not, be indicative of future health risks.
The background: Last month, the FDA gave 23andMe the green light to tell customers whether they have three specific genetic variants of the BRCA1 and BRCA2 genes, which are linked to a higher risk of breast and ovarian cancer. The results will be available through 23andMe’s $199 health and ancestry service.
The backlash: Some critics say it’s irresponsible to provide consumers with this information directly and that people should instead seek out a test ordered by a medical professional who can interpret the results.
23andMe replies: In an editorial published today by Stat, Wojcicki says people should have “more direct access to personalized information so they can take charge of their health” and compares her company’s BRCA test to at-home pregnancy tests, which doctors were initially wary about.
What the future holds: Last year, 23andMe got permission from the FDA to directly tell consumers their risk of developing 10 different diseases, including late-onset Alzheimer’s disease and Parkinson’s, as indicated by their DNA. On top of its new BRCA test, a 23andMe spokesperson told MIT Technology Review, the company plans to launch additional genetic health risk reports for more diseases in the future.
Deep Dive
Biotechnology and health
How scientists traced a mysterious covid case back to six toilets
When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.
An AI-driven “factory of drugs” claims to have hit a big milestone
Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology
The quest to legitimize longevity medicine
Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.
There is a new most expensive drug in the world. Price tag: $4.25 million
But will the latest gene therapy suffer the curse of the costliest drug?
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.